Physician profile
Thaju Salam
NPI 1295794733
$10,520.53
in general payments reported to CMS, 2019-2025
37 companies · $675 in 2025
The $675 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,538 · 2020: $404 · 2021: $1,105 · 2022: $4,000 · 2023: $1,510 · 2024: $1,289 · 2025: $675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,473.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,915.73 | 2021-2025 | Ffrangio, Micra |
| Amgen INC. | $1,182.70 | 2019-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $928.60 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Boston Scientific Corporation | $861.27 | 2019-2025 | Watchman Access System, Watchman Flx, Cds - Mct/Cem Monitoring |
| Pfizer INC. | $625.73 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $585.73 | 2019-2025 | |
| Novo Nordisk INC | $578.18 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Abbott Laboratories | $494.78 | 2021-2025 | Mitraclip, Amplatzer Amulet, Jot Dx |
| Merck Sharp & Dohme LLC | $316.76 | 2021-2025 | Verquvo, Winrevair |
| Astrazeneca Pharmaceuticals LP | $316.04 | 2019-2024 | Farxiga, Andexxa |
| Irhythm Technologies, INC. | $278.72 | 2019-2024 | Zio Xt Patch, Zio Monitor |
| E.R. Squibb & Sons, L.L.C. | $273.49 | 2019-2025 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $269.11 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $235.31 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.37 | 2019-2025 | Jardiance |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thaju Salam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.